Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
We set the pace for forward-thinking kidney care. And we're moving fast. Our team of deeply passionate, innovative, and creative people works nonstop to deliver superior care that improves the quality of life of every patient, every day—because we all deserve to live the most fulfilling life possible.
In our constant pursuit of excellence, we're always expanding what it means to care for people living with kidney disease and other chronic conditions. Today, we've grown into an industry-leading network of more than 2,400 dialysis centers. Our approach to care has made us the industry leader in holistic coordinated care.
We are the nation's only vertically integrated renal company, which means we can move from scientific discovery to patient care faster and more effectively. We also provide pharmacy and laboratory services, pioneering research, and the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. We believe our unified approach helps improve patient health outcomes and reduce the total cost of care. It is our hope that every healthcare provider will embrace this transition to value based care for the benefit of patients.
We're honored to serve patients with cutting-edge services, products, technology, and research, and we're proud to help every person thrive, not just survive.